High response rates, long-term remissions seen in trials of personalized cellular therapy CTL019 for pediatric and adult blood cancers

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over one year in 18 patients and over two years in nine patients. In an emerging new use of the same therapy, known as CTL019, more than half of patients (15 of 28) with non-Hodgkin lymphoma (NHL) also responded to infusions of the personalized cellular thera...